Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase

被引:53
作者
Hu, M [1 ]
Li, YQ
Davitt, CM
Huang, SM
Thummel, K
Penman, BW
Crespi, CL
机构
[1] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Pullman, WA 99164 USA
[2] Washington State Univ, Electron Microscope Ctr, Pullman, WA 99164 USA
[3] Dupont Merck Pharmaceut Co, Newark, DE 19714 USA
[4] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
[5] GENTEST Corp, Woburn, MA 01801 USA
关键词
Caco-2; cells; transfection; CYP3A4; oxidoreductase; transport characteristics;
D O I
10.1023/A:1018986605929
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
Purpose. To further characterize CYP3A4-transfected Caco-2 cells with regard to morphological, transport, and metabolic properties, and to evaluate a different Caco-2 cell strain transfected with both CYP3A4 and oxidoreductase (OR). Methods. Transfected Caco-2 cells, Caco-2 TC7 cells, and wild-type Caco-2 cells grown onto Millicell(TM) were used. We determined the morphological characteristics of transfected cell monolayers using light and transmission electron microscope. We determined the transport and metabolic capabilities of the transfected cells, TC7 cells, and wildtype cells with a variety of drugs, nutrients, and marker compounds. Results. The transfected Caco-2 cells formed a tight monolayer with TEER values and mannitol transport similar to the untransfected parent cell strain (wild type). However, the transfected cells (grown onto Millicell(TM) reached maturity approximately 33% faster than the wildtype cells. Permeabilities of propranolol, nifedipine, testosterone, linopirdine, mannitol, and cephalexin were similar in transfected and wildtype Caco-2 cells. On the other hand, the transfected cells of early passages were much more metabolically active, and metabolized standard CYP3A4 substrates (e.g., testosterone and nifedipine) as much as 100 times faster than untransfected cells. in addition, metabolism of standard substrates was inhibitable by ketoconazole and TAO. Using comparable data, the transfected cells metabolized testosterone the fastest, followed by linopirdine and nifedipine (approximate ratio: 10:6:2). The metabolites of standard substrates were generally preferably excreted to the apical membrane. Conclusion. The monolayers of newly transfected cells (CYP3A4 + OR) have a significantly increased level of CYP3A4 activities compared to untransfected cells. These cell monolayers also have desirable morphological and transport characteristics that are similar to untransfected cells.
引用
收藏
页码:1352 / 1359
页数:8
相关论文
共 17 条
[1]
CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[2]
BACK DJ, 1987, ALIMENT PHARM THER, V1, P119
[3]
EXPRESSION OF CYTOCHROME-P-450 3A IN HT29-MTX CELLS AND CACO-2 CLONE TC7 [J].
CARRIERE, V ;
LESUFFLEUR, T ;
BARBAT, A ;
ROUSSET, M ;
DUSSAULX, E ;
COSTET, P ;
DEWAZIERS, I ;
BEAUNE, P ;
ZWEIBAUM, A .
FEBS LETTERS, 1994, 355 (03) :247-250
[4]
Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4 [J].
Crespi, CL ;
Penman, BW ;
Hu, M .
PHARMACEUTICAL RESEARCH, 1996, 13 (11) :1635-1641
[5]
The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[6]
DIAMOND S, 1994, DRUG METAB DISPOS, V22, P65
[7]
Gan LSL, 1996, DRUG METAB DISPOS, V24, P344
[8]
GRUSHKINLERNER L, 1995, CELL LINE, V5, P1
[9]
MECHANISMS OF TRANSPORT OF QUINAPRIL IN CACO-2 CELL MONOLAYERS - COMPARISON WITH CEPHALEXIN [J].
HU, M ;
ZHENG, LX ;
CHEN, JY ;
LIU, LJ ;
ZHU, YP ;
DANTZIG, AH ;
STRATFORD, RE .
PHARMACEUTICAL RESEARCH, 1995, 12 (08) :1120-1125
[10]
Peptide transporter function and prolidase activities in Caco-2 cells: A lack of coordinated expression [J].
Hu, M ;
Zheng, LX ;
Chen, JY ;
Liu, LJ ;
Li, YQ ;
Dantzig, AH ;
Stratford, RE .
JOURNAL OF DRUG TARGETING, 1995, 3 (04) :291-300